Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Stock Report

| More

AstraZeneca receives marketing permission for Osimertinib

Posted On: 2018-08-09 11:24:35

AstraZeneca Pharma India Limited (AZPIL) today announced that it has received Import & Market permission additional indication for osimertinib (TagrissoTM) Tablet 40 mg and 80 mg, as 1st line treatment for EGFRm advanced Non-Small Cell Lung Cancer (NSCLC) by the Drug Controller General of India (DCGI). The receipt of this permission paves way for the launch of osimertinib in India for 1st line treatment.

Osimertinib is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitutions mutations.

Osimertinib is already approved and available for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an appropriate test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy. AstraZeneca has been pioneering access to T790M mutation testing in India through interventions in infrastructure, scientific knowledge dissemination to medical and pathological experts and standardization of test quality through independent External Quality Assurance (EQA) programs.

In 2017, osimertinib was granted 'Breakthrough Therapy' status and 'Priority Review' designations by the US FDA in 1st line treatment setting. osimertinib is a patented product of AstraZeneca group.

Mr. Gagan Singh Bedi, Managing Director, AstraZeneca Pharma India Limited said, "Lung cancer is the leading cause of cancer related mortality in India. Inspite of therapeutic advances, the overall 5-year survival rate of lung cancer is dismal at <5% in India. Tagrisso's approval in first line treatment is an exciting advance in bringing a potential new standard of care to patients with EGFRm advanced NSCLC in India. Clinical data suggests early and sustained benefit with Osimertinib in first line treatment that has the potential to significantly impact long-term patient outcomes and help address the considerable unmet need that remains in the treatment of lung cancer."

Lung cancer is the leading cause of cancer related mortality world-wide and amongst males in India with 5-years survival rates as dismal as 3.7% in India. Various studies have suggested that nearly all the lung cancer cases are non-small cell lung cancers (NSCLC), of which EGFR-TKI sensitising mutations are observed in 23 50% of patients. These patients are particularly sensitive to EGFRTKIs, which block the cell-signaling pathways that drive the growth of tumour cells. However, tumours almost always develop resistance to EGFR-TKI treatment, leading to disease progression.

Nearly 28-54% of EGFRm advanced NSCLC patients, whose disease progresses after treatment with an EGFR TKI, develop resistance due to the T790M resistance mutation. There is also a need for medicines with improved CNS efficacy since approximately 16% patients with EGFRm NSCLC have brain metastases at diagnosis, increasing to approximately half of patients within 3 years of diagnosis.

Osimertinib (Tagrisso) is a third-generation, irreversible EGFR-TKI designed to inhibit both EGFR sensitising (exon 19 deletions or exon 21 (L858R) substitutions mutations) and EGFR T790M resistance mutations, with clinical activity against CNS metastases.

Shares of ASTRAZENECA PHARMA INDIA LTD. was last trading in BSE at Rs.1735 as compared to the previous close of Rs. 1710.15. The total number of shares traded during the day was 6483 in over 975 trades.

The stock hit an intraday high of Rs. 1808.85 and intraday low of 1710. The net turnover during the day was Rs. 11391871.

Source: Equity Bulls

Click here to send ur comments or to

Other Headlines:

Tiger Logistics India Limited Q1FY19 PAT Rs. 2.3 crores

Barauni-Guwahati Natural Gas pipeline work gathers pace

Astrazeneca receives Marketing Permission for Olaparib Tablet for treatment of Ovarian and Breast Cancer in India

The Improvement Service signs new contract with TCS to Deliver Further Digital Transformation to Scottish Households

Solix Announces Solix EMPOWER New York 2018

India Ratings and Research upgrades India Glycols Ltd's rating

PB Global Ltd Q1 net profit at Rs. 0.43 crore

Thinking global and acting local - Three Phase Electric rolls out Common Sense Smart Community Internet of Thingsservice

Cosmo Films launches CPP metalized film with high metal bond

Ion Exchange India Ltd secures Rs. 438.84 crores order from Vedanta Ltd

Lemon Tree Hotels Ltd signs license agreement for 90 room property at Vijayawada

Rama Steel Tubes Ltd Q1 net profit up at Rs. 3.72 crores

MCX Inks MoU with Indian Bullion and Jewellers Association

Maruti Suzuki announces Price Increase across models

Renaissance Jewellery Ltd. Receives 44Th GJEPC Award For Largest Exporter Of Studded Precious Metal Jewellery

NBCC India Ltd secures order of Rs. 228 crores in July 2018

Orient Abrasives Ltd updates on operations at its plant

V-Mart Retail Ltd opens 2 new fashion stores in UP, Jharkhand

Elantas Beck India Ltd gets environmental clearance for expansion project

NBCC India Ltd receives order from SAIL

Satin Creditcare Network Limited registers 42.8% growth in Gross Loan

Carborundum Universal Limited on the impact of Kerala Rains on its operations

Zeal Aqua Ltd board approves 1:2 bonus issue

Virinchi Limited announces Q1 FY19 Results

Indsil Hydro Power & Manganese Ltd suspends power plant operation due to floods

Hindustan Organic Chemicals Ltd Q1 PAT zooms to Rs. 40.19 crores

Sambhaav Media Ltd commences 91.9 MHz FM radio station at Junagarh

Ashnisha Industries Ltd to increase stake in EZI Ventures Pvt. Ltd. to 64.63%

Mindteck India Ltd reports financial results for Q1 2018-19

Intense Technologies Ltd announces 1st quarter results

Trigyn Awarded - Seattle Public Schools - Staffing Services Contract

Auroma Coke Ltd Q1 net profit jumps to Rs. 0.51 crore

LIME Chemicals Ltd posts net profit of Rs. 1.37 crore in Q1FY19

Sreechem Resins Ltd reports Q1 loss of Rs. 0.03 crore

Alfa Transformers Ltd receives order of Rs. 17.11 crores

Pritika Auto Industries achieves highest ever monthly production volume of 3180 tonnes in July 2018

Cox & Kings Ltd upates on credit ratings

Solix Wins 2018 Frost & Sullivan Award for Global Enterprise Data Platforms Product Leadership

Australia's leading auto repair service provider TRUSTS Ramco HCM

Pfizer Ltd appoints Mr. Milind Patil as CFO

Akar Auto Industries Ltd approves appointment of independent director

Bobshell Electrodes Ltd Q1 net profit at Rs. 0.13 crore

LGB Forge Ltd posts net profit in Q1FY19

Kilitch Drugs India Ltd registers robust growth in Q1FY19

BEML flags off Nation's first 150T Electric Dump Truck

Ashok Leyland introduces 'Innoline' - World's first BS4 Engine driven by an Inline Fuel Pump

JHS Svendgaard Laboratories Ltd - Management comments on Q1FY19 results

Vedanta Limited clarifies on Madras HC notice

Grasim Industries Ltd announces excellent performance in Q1FY19

Navneet Education Limited board to consider buy back on Aug 20, 2018

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2018